813449-00-2

Usage

Benzimidazole family

A group of chemical compounds 1H-Benzimidazole, 6-bromo-1-ethyl (9CI) belongs to this family, which is known for its diverse biological activities.

Derivative

Modified version of benzimidazole 1H-Benzimidazole,6-bromo-1-ethyl-(9CI) is a derivative of benzimidazole with specific structural modifications, including an ethyl group at position 1 and a bromine atom at position 6.

Ethyl group

-CH2CH3 at position 1 An alkyl group is attached to the benzimidazole core at the first position, contributing to the compound's structure and properties.

Bromine atom

Br at position 6 A halogen atom is present at the sixth position of the benzimidazole core, which can influence the compound's reactivity, polarity, and lipophilicity.

Potential applications

Pharmaceuticals and agrochemicals Due to its biological activities and structural features, 1H-Benzimidazole, 6-bromo-1-ethyl (9CI) may have uses in the pharmaceutical and agrochemical industries.

Further research needed

To understand potential uses and effects While 1H-Benzimidazole,6-bromo-1-ethyl-(9CI) shows promise, more studies are required to fully comprehend its possible applications and impact on various fields.

Upstream product

• 875-51-4 4-Bromo-2-nitroaniline 
• 74-96-4 ethyl bromide 
• 4887-88-1 5-bromo-1H-benzo[d]imidazole 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Relevant academic research and scientific papers

Hetero- A nd Homobimetallic Complexes Bridged by a Bis(NHC) Ligand: Synthesis via Selective Sequential Metalation and Catalytic Applications in Tandem Organic Transformations

A (bis)azolium salt [L1-H2]Br2 (5), synthesized following multistep procedures, was realized to be a suitable platform for accessing the bis(NHC) ligand supported heterobimetallic IrIII-M (M = PdII/AuI) complexes via a sequential metalation strategy for their potential catalytic applications in one-pot tandem organic transformations. First, the reaction of 5 with 0.5 equiv of [Ir(Cp-)Cl2]2 selectively yielded a monometallic IrIII complex 6, which was further metalated using Pd(OAc)2/NaOAc to afford the heterobimetallic IrIII-PdII complex 7. On the other hand, complex 6 was reacted with Ag2O, followed by transmetalation with [Au(SMe2)Cl] in a one-pot manner, to yield the IrIII-AuI complex 8. Further, the related homobimetallic IrIII and PdII complexes 9 and 10, respectively, have also been synthesized directly from [L1-H2]Br2. All the homo/heterobimetallic complexes have been well-characterized by multinuclear NMR spectroscopy, ESI-mass spectrometry, and via single-crystal X-ray diffraction studies of the complexes 7, 8, and 10. The heterobimetallic IrIII-PdII complex 7 has been tested as a catalyst for three one-pot tandem catalytic reactions: (a) Suzuki-Miyaura coupling and transfer hydrogenation of ketones, (b) hydrodefluorination and transfer hydrogenation of ketones, and (c) hydrodehalogenation and transfer hydrogenation of imines. Importantly, the catalytic activity of heterobimetallic complex 7 in the above-mentioned reactions was found to be better than the mixture of their corresponding homobimetallic counterparts 9 and 10, keeping the concentration of the metal centers constant. These observations affirm some sort of cooperativity between the two metal centers (Ir and Pd) connected via a single ligand frame in 7 when catalytic activity is concerned, which thus constitutes a superior catalytic system than that of the cases where two separate metal complexes (hence, the two metal centers are not connected by a single ligand framework) are used.

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.